Home    Back

Hmed-ides    (DrugBank: HMED-IdeS, IdeS)

2 diseases
IDDisease name (Link within this page)Number of trials
64Thrombotic thrombocytopenic purpura0
221Anti-glomerular basement membrane disease1

64. Thrombotic thrombocytopenic purpura    [ 74 clinical trials,   76 drugs,   (DrugBank: 19 drugs),   15 drug target genes,   57 drug target pathways]
Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 74 trial found

221. Anti-glomerular basement membrane disease    [ 1 clinical trial,   3 drugs,   (DrugBank: 1 drug),   0 drug target gene,   0 drug target pathway]
Searched query = "Anti-glomerular basement membrane disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03157037
(ClinicalTrials.gov)		March 1, 201711/5/2017An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDESAnti-Glomerular Basement Membrane DiseaseBiological: HMed-IdeSMårten SegelmarkHansa Biopharma ABCompleted18 YearsN/AAll15Phase 2Austria;Czechia;Denmark;France;Sweden